H. Chung

发表

Whole genome analysis for liver metastasis gene signatures in colorectal cancer

S. Rha, H. Jeung, D. Ki, 2007, International journal of cancer.

Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer

R. Schlegel, S. Rha, R. Leach, 2003, Molecular pathology : MP.

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.

A. Jimeno, A. Nagrial, D. Rasco, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer.

J. Roh, S. Rha, J. Min, 2001, Cancer letters.

Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial.

Y. Bang, J. Ji, Y. W. Kim, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

S. Song, H. Chung, J. Cho, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).

J. Lunceford, T. Mcclanahan, M. Ayers, 2015 .

Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer.

J. Roh, S. Shin, S. Noh, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.

J. Roh, S. Rha, H. Chung, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of the ABCB 1 gene polymorphisms 2677 G > T / A and 3435 C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients

J. Roh, S. Rha, H. Chung, 2009 .

Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy

S. Noh, S. Rha, H. Jeung, 2002, The British journal of surgery.

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.

J. Ajani, Y. Bang, Z. Wainberg, 2019, European journal of cancer.

Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gastric cancer.

J. Roh, J. Min, H. Chung, 1995, Oncology.

Coexisting mycosis fungoides and Hodgkin's disease as a composite lymphoma: a case report.

H. Chung, G. Kim, J. H. Kim, 1991, Yonsei medical journal.

Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial.

M. Fujii, W. Koizumi, H. Chung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

S. Oh, S. Sym, I. Chung, 2020 .

O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

C. Fuchs, M. Mandalà, C. Shih, 2020 .

JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Y. Bang, Keun-Wook Lee, C. Yen, 2018 .

Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study.

R. Kelley, A. Nagrial, D. Oh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Cetuximab in Combination with Capecitabine and Cisplatin as First-Line Treatment in Advanced Gastric Cancer: Randomized Controlled Phase III Expand Study

F. Lordick, G. Bodoky, S. Oh, 2012 .

HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial

A. Sawaki, H. Chung, L. Shen, 2008 .

LBA15A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER

R. Berger, Y. Bang, M. Dolled-Filhart, 2014 .

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

J. Roh, S. Shin, S. Noh, 2007, British Journal of Cancer.

Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.

Jianming Xu, K. Yeh, A. Ohtsu, 2010 .

1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Y. Bang, N. Sugimoto, D. Sakai, 2020 .

Multicenter phase II study of a cremophor-free polymeric micelle-formulated paclitaxel in patients (pts) with metastatic breast cancer (MBC).

S. Im, H. Chung, J. Ro, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases.

J. Roh, S. Noh, S. Rha, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial.

Y. Bang, Yoon-Koo Kang, K. Muro, 2018 .

Relationship between p53 overexpression and gastric cancer progression.

D. Shin, J. Roh, S. Noh, 1997, Oncology.

LBA28_PRKEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

Y. Bang, C. Fuchs, G. Ku, 2017 .

Adjuvant 5‐fluorouracil plus doxorubicin in D2‐3 resected gastric carcinoma

H. Chung, S. Noh, S. Rha, 2001, Cancer.

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

E. Van Cutsem, M. Alsina, M. Lichinitser, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Alpha-fetoprotein-producing gastric cancer.

S. Noh, S. Rha, J. Min, 1998, Oncology reports.

LAMC2 enhances the metastatic potential of lung adenocarcinoma

Ji Luo, Yi-Song Wang, G. Giaccone, 2015, Cell Death and Differentiation.

Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.

J. Roh, S. Noh, S. Rha, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Interim report for a phase II, multi-centre, dose-escalating study of LB80380/ANA380 in hepatitis B patients with lamivudine-resistant YMDD mutant HBV

M. Yuen, S. Yoon, H. Chung, 2005 .

External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer.

J. Kim, C. Nam, S. Noh, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)

P. Beale, B. Goh, S. Clarke, 2006, Cancer Chemotherapy and Pharmacology.

Establishment and characterization of a tumor cell line from human nasopharyngeal carcinoma tissue.

M. Tsai, H. Chung, S. Y. Lin, 1989, Cancer research.

Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation.

J. Roh, S. Noh, S. Rha, 1998, International journal of oncology.

Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.

J. Roh, C. Kim, S. Noh, 1997, American journal of clinical oncology.

Endotracheal tube fires during carbon dioxide laser surgery on the larynx--a case report.

J. J. Chen, H. Chung, P. Tan, 2001, Acta anaesthesiologica Sinica.

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Kyung Won Lee, K. Lee, Yoon-Koo Kang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

A. Italiano, W. Miller, M. Fakih, 2019, Annals of Oncology.

Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction

H. Chung, H. Jeung, J. K. Roh, 2005, FEBS letters.

Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression.

J. Roh, S. Noh, S. Rha, 1998, Yonsei medical journal.

Correlation of tissue and blood plasminogen activation system in breast cancer.

J. J. Kim, J. Roh, S. Rha, 2000, Cancer letters.

A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.

J. Roh, S. Rha, J. Min, 1997, American journal of clinical oncology.

An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma.

J. Roh, S. H. Park, S. Noh, 1998, Yonsei medical journal.

Primary lymphoma of the thyroid.

C. Suh, J. Hahn, Y. Ko, 1995, Yonsei medical journal.

Retention of broken central venous catheters in pulmonary artery and inferior vena cava--a case report.

H. Chung, P. Tan, Y. Chia, 1997, Acta anaesthesiologica Sinica.

Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate.

A. Wellstein, J. Roh, H. Kwak, 1997, Cancer letters.

Gastric cancer in young patients who underwent curative resection. Comparative study with older patients.

J. Roh, J. Min, H. Chung, 1996, American journal of clinical oncology.

Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast.

J. Roh, S. Rha, J. Min, 1999, International journal of oncology.

Changing trends in histologic types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study.

J. Roh, Jin-Hyuk Choi, Sung Kyu Kim, 1994, Lung cancer.

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.

C. Fuchs, E. Van Cutsem, M. Mandalà, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A

S. Oh, A. Spira, S. Kim, 2021, Annals of Oncology.

Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.

C. Suh, W. Yang, S. Rha, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Experience with a controlled-release oral morphine for cancer pain management.

H. Chung, B. S. Kim, 1991, Postgraduate medical journal.

PD-L1 expression and T-cell inflamed gene expression profile (GEP) in Korean and US patients (pts) with advanced gastric cancer (GC).

J. Ajani, G. Ku, D. Maru, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1413P Antibiotic administration and outcome of patients with advanced gastric cancer receiving programmed death-1 inhibitors or with single-agent chemotherapy

S. Shin, S. Rha, H. Jeung, 2021, Annals of Oncology.

Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.

K. Shin, J. Kim, S. Rha, 1999, Oncology reports.

Fatal anaphylactoid shock associated with protamine for heparin reversal during anesthesia.

H. Chung, P. Tan, C. Kuo, 2000, Acta anaesthesiologica Sinica.

(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer.

Y. Hamamoto, H. Chung, E. Cutsem, 2010 .

M. Azuma, M. Ryu, W. Kang, 2019 .

Tissue urokinase-type plasminogen activator receptor levels in breast cancer.

J. Roh, S. Rha, J. Min, 2000, International journal of molecular medicine.

LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours

Juanita Lopez, E. Castañón, M. Doherty, 2020 .

Gene-expression profiles related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.

S. Rha, H. Chung, H. Kwon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector.

S. Jeong, J. Roh, D. Shin, 1999, Oncology reports.

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

J. Roh, B. Cho, S. Rha, 2006, British Journal of Cancer.

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

Joon-Oh Park, M. Kudo, G. Brandi, 2015 .

A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.

K. Muro, T. Tamura, W. Kang, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain.

Jin-Hyuk Choi, S. Hong, H. Chung, 1996, Oncology.

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study.

C. Fuchs, E. Van Cutsem, J. Tabernero, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study).

I. Hyodo, M. Takeuchi, H. Baba, 2019, Annals of Oncology.

Different expression patterns of MMP-2 and MMP-9 in breast cancer.

J. Roh, W. Yang, S. Rha, 1998, Oncology reports.

Gemcitabine pathway genotype analysis to predict toxicity in phase II gemcitabine monotherapy in heavily pre-treated metastatic breast cancer.

J. Sohn, S. Rha, H. Chung, 2004, Journal of Clinical Oncology.

Male breast cancer--a 20-year review of 16 cases at Yonsei University.

J. Roh, C. Suh, J. Min, 1990, Yonsei medical journal.

Comparison of epidural butorphanol plus clonidine with butorphanol alone for postoperative pain relief.

H. Chung, M. Mok, P. Tan, 1997, Acta anaesthesiologica Sinica.

Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer.

J. J. Kim, J. Roh, S. Rha, 1998, International Journal of Molecular Medicine.

Point mutation at codon 12 of the c-Ha-ras gene in human gastric cancers.

J. Min, H. Chung, J. Youn, 1992, Journal of Korean medical science.

The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy.

J. Roh, J. Min, H. Chung, 1992, Yonsei medical journal.

External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer.

S. Noh, S. Rha, H. Chung, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma

N. Sugimoto, D. Sakai, M. Ryu, 2021, Annals of Oncology.

KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer.

C. Fuchs, M. Mandalà, K. Muro, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.